1 / 65

Guidelines in management of breast cancer (UK experience)

Guidelines in management of breast cancer (UK experience). HAMDY ELMARAKBY MD FRCS. Breast Pain (cyclical or not). No mass, mild pain: - <35 years: reassure and discharge. - > 35 years: mammography No mass, moderate to severe pain: - < 35: ultrasound - > 35: mammography

izzy
Télécharger la présentation

Guidelines in management of breast cancer (UK experience)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Guidelines in management of breast cancer (UK experience) HAMDY ELMARAKBY MD FRCS

  2. Breast Pain (cyclical or not) • No mass, mild pain: - <35 years: reassure and discharge. - > 35 years: mammography • No mass, moderate to severe pain: - < 35: ultrasound - > 35: mammography • Good support bra night and day, reduce caffeine intake, discontinue smoking, low fat diet, change the type of contraceptive pills and • Evening primrose capsules: - Gamolenic acid 240-300mg - 3-4 months at least - Danazol 100mg daily, assess after one month and continue for 6 months if response.

  3. Cystic disease ( fibrocystic or not) • Palpable cysts, 7% of western women. • U/S, Mammography according to the age group. • Aspirate (free hand or ultrasound): - No blood, no residual lump, not re-accumulating: discharge - Rapidly recurrent, or blood: re-image, FNAC ?excision? • Multidisciplinary meeting (MDM).

  4. Breast Cancer : Diagnosis • Monday am clinic (new patient): one stop (triple assessment). • Wednesday pm: multidisciplinary meeting (MDM). - Surgeons, Oncologist, Radiologist, Pathologist, breast care nurses, secretaries • Thursday am: New follow ups • Thursday pm: all other follow ups

  5. Diagnosis • Breast lump, asymmetric thickening, nodularity, nipple discharge. • Triple assessment: clinical examination, radiological (ultrasound, mammography), Biopsy( wide bore needle, FNAC). • P value, U value, R value: 1-5(normal, benign, uncertain, suspicious, malignant). • Any P3,U3, R3 should be biopsied. • One stop clinic: patient will be given another appointment for the results if P3,U3,R3. • FNAC is only used with too small or inaccessible lesions and with nipple discharge. • All discordant results should be discussed in the MDM.

  6. Ultrasound/Mammography • Ultrasound: breast abnormalities in ages <35 years, however, • It should not used in pain, and not as screening tool. • Mammography: - Breast abnormalities in ages >35 years. - National screening programme >50 years. - Early Screening (age < 50years,+family). - Nipple discharge. - Follow up in diagnosed breast cancer.

  7. MRI • Ill defined tumours/ breast conservative surgery. • Multifocal disease? • Assessment of the integrity of breast prosthesis?. • Decision should be made at the MDM as mammography has taken over.

  8. Excision biopsy • Diagnostic uncertainty on core biopsy or FNAC. • Lump >30mm in all age groups. • Discuss and consider excision of all lumps in > 35 years even if P2,R2. • MDM discretion

  9. Breast Discharge • Single duct: • FNAC: performed by surgeons. - Benign (c2) or negative for blood: see 3 monthly for a year. - Uncertain (C3) or + ve for blood: consider surgery ( micro- dechoctomy <50 years, macro- dechoctomy>50 years). • MDM

  10. Breast Discharge, continued • Multiduct: - Bilateral: benign (c2) or negative for blood, reassure and discharge. - Unilateral: same criteria /follow up 3 monthly for a year. - Uncertain (C3) or + ve for blood, or troublesome: consider mammmo dechoctomy after discussion in MDM. • Consider hyper prolactinaemia or drug induced galactorhea if profuse bilateral and embarrassing.

  11. Other investigation tools • All patients should have FBC, LFT, CXR and bilateral mammogram. • No routine bone scan or liver US for operable breast cancer unless abnormal routine tests or if symptoms suggestive of metastasis.

  12. Surgery • D.C.I.S. • Operable breast cancer. • Locally advanced disease.

  13. Non surgical treatment • Adjuvant chemotherapy. • Adjuvant hormone treatment. • Adjuvant Radiotherapy. • Neo-adjuvant Chemotherapy.

  14. Male breast cancer • <1% of breast cancer and < 1% of all male cancers. • Guidelines are essentially the same as female breast cancer. • Clinical outcome when matched for age, stage and treatment protocol are similar to females ( Perkins and Middleton BMJ 2003).

  15. Surgery for early breast cancer • Non invasive breast cancer (DCIS): - No absolute consensus. - Lesions < 4cm: WLE with 1cm safety margin. No axillary surgery. - Lesions > 4cm or multifocal consider mastectomy. - Axillary node sampling if extensive multifocality (1-5% lymph node involvement) ( Dixon 1998) - DXT: beneficial - Hormonal treatment: less certain ( Lancet IBIS trial 2003). • Lobular carcinoma in situ (LCIS): a marker lesion for increased risk of invasive cancer/close surveillance.

  16. WLE

  17. WLE+ Augmentation Mammoplasty

  18. Invasive Breast Cancer (Early) • Breast Conservative Tumour (BCT): solitary <3cm, or selected cases with > 3cm in large breast (MDM). • Contraindications: - multifocal, - recurrent disease after BCT, - patient choice, - tumour > 3cm, - centrally placed tumors, or - if DXT is contraindicated, - pregnancy, - age< 35 years( MDM).

  19. Breast Conservative Surgery (BCS) • A cylinder of breast tissue from skin to deep fascia is removed. • No skin is removed unless superficial tumor. • Macroscopic radial margins should be at least 10-20mm and microscopic margins at least 5mm. • Radiopaque clips: 1( anterior surface),2(medial surface), 3(inferior surface). • Silk suture on tissues closest to nipple.

  20. Breast conservative surgery

  21. What’s next • Specimen x ray for all cases with a detectable mammographic abnormality. • If close margin: immediate re-excision at same operation. • 4 axillary node sampling if axillary clearance is not indicated. • ER and PR status in all patients. • Mark the cavity with 4 clips on the pectoral fascia for DXT( superior, inferior, medial and lateral).

  22. Treatment of axilla • Incidence: 1%(DCIS),5%-28%(T1), 48%(T2), 68%(T3), 88%(T4). • Axillary sampling (4 node): - if clinically N0 • Axillary clearance: if N1 or +FNAC and if mastectomy is indicated for recurrent disease. • Not indicated if previously treated with radiotherapy.

  23. Locally advanced Breast Cancer • large cancer(T3-4), skin or muscle or chest wall infiltration, matted L.N. • Full screen for metastasis( bone scan, liver US, possible CT chest). • MDM: select cases for adjuvant chemotherapy and hormonal ttt (Cancer;98:1150-60, 2003).

  24. Locally advanced Breast Cancer • Hormonal: slowly growing, ER PR+, unfit patients for chemotherapy. • Chemotherapy: inflammatory carcinoma, ER, PR –ve, young patient <35. • Value: down staging, • Definitive surgery will entirely depend on the tumor response.

  25. Chemotherapy • Adjuvant( in addition)/Neo-adjuvant (in advance/instead) of surgery. • Details pathology: tumour size, grade, nodal, receptor status, margins of excision and the presence or absence of vascular or lymph-vascular invasion. • Indications (risk factors): +ve nodes, grade 2-3, size>2cm,vascular invasion and receptor –ve tumors. • Anthracycline based e.g. 6 cycles of Epirubicin,5FU, Cyclophosphamide. Other combinations Epirubicin, Cyclophosphamide and Taxane.

  26. Chemotherapy continued • HER2 receptor status is becoming increasingly important particularly in relapse patients who are candidates for Trastuzumab (Herceptin). • The benefits of chemotherapy in postmenopausal patients is increasingly appreciated making the traditional classification of patients into pre and post menopausal less crucial. • Chemotherapy is not routinely offered to patients>65years.

  27. Hormonal therapy • All patients with estrogen/ progesterone receptors positive. • Tamoxifen 20mg/day for 5 years. • Exceptions: previous tamoxifen therapy or history of thrombo-embolism. • Should not simultaneously prescribed with DXT for fear of increased risk of pulmonary fibrosis. (Radiother Oncol 2002,Br J Cancer 2004). • Should not simultaneously prescribed with chemotherapy as it reduce its effect and significantly increase the incidence of thromboembolism. • ATTOM trial 5 more years of tamoxifen after finishing a 5 year treatment. Provided that the patients are disease free and had a complete resection of tumors.

  28. Arimidex (Anastrozole) • A non steroidal aromatase inhibitor. • ATTAC trial suggests: it is stronger with better prognosis and lesser side effects than tamoxifen. • Nevertheless more arthralgia and fractures complication (Lancet 2005). • Receptor +ve postmenopausal.

  29. Adjuvant Radiotherapy • Post BCS: DXT is given to the breast and the lower axilla in the tangential glancing fields. • DXT should be considered for all patients with completely excised DCIS who had undergone BCS. • Only those with lesions <10mm should be discussed at the MDM. • 4500-5000 cGY in 20-25 fractions daily. Options to give boost in younger patients. • DXT to supraclav. L.N: Should be considered with 4 or more pathologically involved axillary L.Ns, apical nodes involvement and with extra nodal spread of tumor.

  30. Post-mastectomy Radiotherapy • Chest wall: - 4 or more pathologically involved axillary nodes, - primary tumor >5cm(large breast) - and tumor 3-5cm( small breast), - narrow deep margin <0.5cm, - evidence of lymph vascular invasion. • Irradiation to the axilla is only for those who have not had axillary clearance.

  31. Follow up • Access to breast care nurse/unscheduled outpatient review and for post 5 years follow ups. • Patients are seen for 5years in the breasts cancer follow up clinic starting from 2 weeks postoperative where the results are conducted. • Alternating appointment every 3months between the oncologist and the surgeon for 2 years, then very 6 months for 3years. • Clinical examination to the breast and the lymph nodes.

  32. Follow UP • Mammography is requested annually for 5 years. • After 5 years if < 50years, arrange biennial mammography until 50years. • if>50years then discharge to NHSBSP for 3yearly screening. • IF>70years self referral for 3yearly screening. • All patients diagnosed with distant metastasis should stop mammography surveillance. • Other investigations are only requested if symptoms develop e.g. back pain, lump, rash etc

  33. Breast reconstruction • Patients should be aware prior to surgery for the possibility of breast reconstruction. • Primary? Delayed? • All patients should be offered the opportunity to meet another patient who underwent BR.

  34. Breast Reconstruction

  35. Breast reconstruction

  36. Quality standards • All patients with suspected breast cancer should be seen by specialist within 2 weeks of GP referral. • More than 90% of GPs must receive feed back from the breast unit within one week of patients appointment. • One stop clinic: Clinical, imaging, biopsy should be performed at the initial visit.

  37. Quality standards • >90% of patients should be diagnosed preoperatively. • <10% of patients should attend the hospital for more than one visit for diagnostic purposes. • >90% of diagnosed patients should be admitted for surgery within 2 weeks and 100% within 4 weeks. • BCS, BCN, MDM are compulsory.

  38. Outcome of breast cancer • 60% of patients will develop some form of recurrence, 2/3(40%) will develop within 5 years. • 50% will eventually present with distant metastasis and die from the disease. • Nottingham prognostic index (NPI): Grade(1-3)+ N Stage (N 0-2)(1-3)+ (0.2xsize of tumor in cm)

  39. Outcome of breast cancer • No (negative axilla), N1 (low axilla}, N2 (high axilla). • Good (score<3.4)(80% 10 year survival ),moderate (score 3.4-5.4)(40% 10 year survival) , poor (score >5.4) (15%10 year survival). • Example: 2cm,G2,N1= 0.4+2+2= 4.4 =moderate

  40. Family history • Genetic predisposition in 5-10%. • However 15% of patients give family history. • Pedigree analysis questionnaire and qualitative risk assessment will be made. • Refer to regional genetic cancer clinic.

  41. Family History • Risk factors: a close female relative had breast cancer <40, or had bilateral breast cancer or • 2 close female had breast cancer < 60 or one had breast and the other had ovarian cancer or both had ovarian cancer. • A male close relative had breast cancer at any age. • A close relative denotes a first and second degree. • Refer to regional cancer genetic clinic. • Moderate and high risk female will have an annual clinical assessment and mammography starting from the age of 35- 40 years. • At 50 years they are discharged back to the NHSBSP

  42. Thank you

More Related